Speaker Profile
Vice Chair & Director of Impact and Donor Relations, Association for Creatine Deficiencies
Biography
Jeffrey Randall Allen is a rare-disease advocate whose work is driven by his son Lucas, who was diagnosed with Creatine Transporter Deficiency (CTD) in 2019. He brings nearly 20 years of healthcare sales and business development experience across medical devices and medtech and now serves as Vice Chair & Director of Impact and Donor Relations at the Association for Creatine Deficiencies. Allen became widely known as the Season 1 champion of MrBeast’s Beast Games, winning the $10 million grand prize and using the visibility to accelerate awareness and funding for CTD research. He has since led Ruck4Rare fundraising campaigns and pledged $1 million to ACD’s Race for a Cure. His perspective bridges patient urgency, philanthropy, advocacy and the challenge of moving promising rare-disease science toward scalable treatments.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Catriona Jamieson, UC San Diego
PMWC Award Ceremony
• Emmanuelle Charpentier, Max Planck (J. Craig Venter Visionary Award · Nobel Laureate)
• Jay Bradner, Amgen (Pioneer)
• Adrian Krainer, Cold Spring Harbor Laboratory (Luminary)
• Randy Schekman, UC Berkeley (Nobel Laureate, Pioneer)
Featured Speakers
• Emmanuelle Charpentier, Max Planck
• Randy Schekman, UC Berkeley
• Jay Bradner, Amgen
• Adrian Krainer, Cold Spring Harbor Laboratory
• Alexis C. Komor, UC San Diego
• Nicole Gaudelli, GV
• Rachel Haurwitz, Caribou Bio
• Gene Yeo, UC San Diego
• Timothy Yu, Boston Children's / Harvard
• Shicheng Guo, Arrowhead Pharmaceuticals
• Mark A. Kay, Stanford
• Niren Murthy, UC Berkeley
• Ben Deverman, Broad Institute
• Stanley Crooke, n-Lorem / Ionis
Programming Protein Fate
Molecular glues, degraders, and induced proximity crossing into medicines.
Genome Editing Beyond the First Wave
Base, prime, and CRISPR-enabled editing moving from correction to clinic.
RNA Editing, Splice Modulation & Programmable RNA
RNA editing, ASOs, and splice modulation with chemistry already reaching patients.
In Vivo Delivery & Vector Engineering
AAV, LNP, and next-generation vectors that decide what is treatable.
From N-of-1 to Platform
Evidence, CMC, regulation, and access for individualized genetic medicines.
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
